Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Yield10 Bioscience Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Yield10 Bioscience (NASDAQ:YTEN) reported Q1 sales of $149.00 thousand. Earnings fell to a loss of $3.33 million, resulting in a 11.78% decrease from last quarter. In Q4, Yield10 Bioscience brought in $152.00 thousand in sales but lost $2.98 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.